POS1607 BIOLOGICS THERAPIES FOR PSORIASIS DECREASE FUTURE RISK FOR DEVELOPING PSORIATIC ARTHRITIS

Background Psoriasis (PsO) is an inflammatory skin disorder with estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) highly associated higher severity PsO, present in up to 30% patients and 0.3–1.0% the global population PsA typically develops after PsO [1,2]. There are some contradictory studies relationship impact biological therapies for prevention PsA. Objectives To ascertain whether pre-existing psoriasis may reduce incidence psoriatic according different treatment regimens ranging from topical therapy therapy. Methods We conducted a retrospective exploratory study real-world data third largest Israeli health maintenance organization, ‘Meuhedet’ which covers approximately 1,300,000 subjects. All ‘Muehedat’ diagnosed January 2000 until 2020 were included analysis. Overall, 61,003 detected. In addition, each patient was paired four control subjects by gender, age, ethnicity. Patients before diagnosis or less than six months excluded defined physicians’ diagnoses. either peripheral axial arthritis. classified their treatment; Group 1-topical therapy, phototherapy no 2 - conventional DMARDs (cDMARDs; methotrexate sulfasalazine), 3 -biologics (bDMARD) The incident cases analyzed aforementioned lines bDMARDs group further sub-grouped first-line prescribed treatment. Time-dependent Cox proportional hazard models used evaluate adjusted risk developing group. Data analysis Python Software Foundation, Language Reference, version 3.9.12, R 4.2.0, RStudio (RStudio Team, 2020), ‘Survival’ package (v3.2; Therneau, 2020). Results 58,671 contributing total 628,228 patient-years. This body mass index (BMI), age diagnosis, time treatment, number treatments lines. Adjusted hazards regression showed that treated cDMARDs significantly comparison those (HR: 2.76, CI: 2.19 – 3.48, p-value: <0.001). On contrary, also decreased agents 0.62, 0.42 0.90, <0.014). Conclusion at alone reflect extent c DMARD been linked Biological References [1]Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, et al. Utilization validated Epidemiology Screening Tool identify signs symptoms among psoriasis: cross-sectional US-based Corrona Registry. Journal European Academy Dermatology Venereology 2019;33:886–92. [2]Wilson FC, Icen Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence clinical predictors A population-based study. Arthritis Care Res (Hoboken) 2009;61:233–9. [3]Koolaee RM, Takeshita J, Ogdie A. Natural History Arthritis: An Update What Dermatologists Need Know. Curr Dermatol Rep 2013;2:66–76. Acknowledgements: NIL. Disclosure Interests None Declared.